All In Biotech

Drug Trial Radar · NCT06386419

A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

A Real-world, Prospective, Multi-center, Open-label, Phase 4 Clinical Study to Evaluate the Safety and Effectiveness of Subcutaneous Injection of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

65

Actual

Start

Nov 12, 2024

Primary completion

Jan 13, 2026

Study completion Jan 13, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to generate post-marketing safety and effectiveness data of inclisiran sodium in Indian patients as per approved indication i.e., primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia that more closely resembles the real-world population intended to be treated with inclisiran sodium.

Conditions

  • Primary Hypercholesterolemia
  • Mixed Dyslipidemia

Interventions

  • inclisiranDrug

    Inclisiran sodium 300 mg SC. Three single doses of inclisiran sodium will be administered to the participants on Day 1, Day 90, and Day 270, respectively

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and type of treatment-emergent adverse events (TEAEs)Time frame: 10 months (300 days)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Bangalore, Karnataka, India

  • Novartis Investigative Site

    Belagavi, Karnataka, India

  • Novartis Investigative Site

    Mumbai, Maharashtra, India

  • Novartis Investigative Site

    Nagpur, Maharashtra, India

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site

    Jaipur, Rajasthan, India

  • Novartis Investigative Site

    Madurai, Tamil Nadu, India

  • Novartis Investigative Site

    Vellore, Tamil Nadu, India

  • Novartis Investigative Site

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.